Share
16,603 Posts.
lightbulb Created with Sketch. 2364
clock Created with Sketch. 12/05/24
01:05
Share
Originally posted by PigRace
↑
One part from the KOL meeting Apr 3, 2024 continues resonating in my mind.Dr. Arshad Khanani on the portion of study participants reaching 20/40 (00:44:20-00:45:00): "I think it's important to look at the baseline VA. It's about about 50.5 letters for the P2b Programme and if you look at Eylea or Lucentis, it's close to 60." 11.9% of patients enrolling with 74 letters or better) 15.4% 74 letters or better) 17.9% 73 letters or better) 19.2% 36.9% 68 letters or better) 32.9% 68 letters or better) P2b (sozinibercept): 25-60 letters only 49.5 letters (25-60 letters only ) 48.6% achieving 20/40 at 24wthe addition of sozinibercept gets a real-world patient with a 50 letters BCVA at start up to a 20/40 vision (= 68-69 letters) with the same probability as an anti-VEGF-A alone does with a 60 letters patient at start .
Expand
And if you're willing to play the game of comparing different trials then perhaps you should look at the recent Eyelea 8mg extended dosing schedule, the one the FDA knocked back.
(20min delay)
